Serinex Medical is a silk biomaterials company developing DuraDerma, a topical silk-fibroin gel designed to strengthen intact skin and prevent pressure injury progression in immobilized patients. Applied twice daily by providers to high-risk contact points, DuraDerma augments standard of care to reinforce skin resilience against mechanical stress and shearing forces, addressing a $26.8 billion U.S. burden.
Funding
Funding not disclosed
Founders
Product
Problem
Pressure injuries are progressive wounds that form in immobilized patients and are a key source of infection. In the U.S., more than 2.5 million cases occur each year, costing over $26.8 billion in care, yet no current products are labeled to reduce the risk of forming a pressure injury or to reduce the risk of progression of early-stage injuries.
Solution
Serinex Medical offers DuraDerma, a topical gel of medical-grade silk fibroin applied alongside standard of care to at-risk points of body contact in bedridden patients. The product acts on intact skin to reinforce its resilience against the mechanical stress and shearing forces that drive pressure injury development and progression, unlike dressings and negative pressure wound therapy that are used on open wounds. Intended for twice-daily application by a provider to high-risk contact points, DuraDerma augments existing protocols rather than replacing them, improving their efficacy. As a preventive rather than reactive solution, DuraDerma is designed to be the first product labeled to prevent pressure injury progression.
Target Audience
Primary customers are healthcare providers and institutions managing bedridden, immobilized patients, including hospitals and advanced wound care centers that treat hospital-acquired pressure injuries.
Features
- Topical gel formulated with medical-grade silk fibroin to strengthen intact skin
- Acts preventatively on intact skin, distinct from dressings and NPWT used on open wounds
- Designed for twice-daily provider application to high-risk contact points in bedridden, immobilized patients
- Augments standard of care protocols to improve efficacy without replacing existing treatments
- Targets reduction of risk for both pressure injury formation and progression of early-stage injuries